EPCs were obtained from mononuclear cells isolated from peripheral blood (100ml) by density gradient method (38 (
link)). “Late” EPCs were obtained from cells collected 3 weeks after RAS induction, and subsequently cultured for 3 weeks, while “early” EPCs were obtained from cells collected and cultured 1 week before infusion (2 (
link)).
EPCs were characterized by fluorescence activated cell sorting (FACS) analysis after immunostaining with monoclonal antibodies against the progenitor markers CD133 (R&D Systems, MN, Cat# AF3890, NS0-derived rpCD34 1:50) and kinase-insert domain receptor (KDR, Santa-Cruz, CA, Cat# sc-504, Clone: C-1158 1:50), as previously described (10 (
link)).
MSCs were isolated from adipose tissue (5–10g) collected from pigs during RVH induction or sham. Tissue was processed for MSC isolation with standard protocol (32 (
link)), and cultured with advanced minimum-essential-medium (Gibco/Invitrogen) supplemented with 5% platelet lysate (Mayo Clinic Transfusion Medicine) in 37°/5% CO2. FACS was used to determine cellular phenotype for the MSC markers CD44 (abcam Cat#: ab10558 1:100) and CD90 (BD Pharmigen Cat#:55593 1:100). Before delivery EPCs and MSCs were labeled with a fluorescent membrane dye (CM-DiI, CellTracker™, Catalog #: C7001, Life Technologies) and kept in cell recovery medium at −80°C for transplantation. Then, 6 weeks after RVH or sham induction, 10^6 cells/mL of EPC (an equal mix of early and late) or MSCs suspended in 10ml of PBS (Life Technologies, # 10010-023) were injected slowly through a balloon catheter (OPTA® Pro PTA Dilatation Catheter, Cordis, New Jersey) placed in the renal artery proximal to the stenosis.
Fluorescent-labeled cells were subsequently manually counted ex-vivo under fluorescence microscopy (ZEN® 2012 blue edition, Carl ZEISS SMT, Oberkochen, Germany) in 5µm LV cross-sections and 5µm renal tissue sections stained with cytokeratin (AbD Serotec, Cat# MCA1907), and their number per field averaged (7 (
link),8 (
link),34 (
link)). Furthermore, EPC and MSC distribution was evaluated by immunofluorescence staining with the distal tubular marker peanut agglutinin (PA, Vector Lab, Cat# FL-1071, 1:500), the proximal tubular marker phaseolus vulgaris erythroagglutinin (PHA-E, Vector Lab, Cat# FL-1121, 1:500), the endothelial marker CD31 (AbD Serotec, Cat# MCA 1747, dilution 1:50), and the proliferating cell nuclear antigen (PCNA, Abcam, Cambridge, MA; Cat# ab29,1:100).
Eirin A., Zhu X.Y., Ebrahimi B., Krier J.D., Riester S.M., van Wijnen A.J., Lerman A, & Lerman L.O. (2014). Intra-renal delivery of mesenchymal stem cells and endothelial progenitor cells attenuates hypertensive cardiomyopathy in experimental renovascular hypertension. Cell transplantation, 24(10), 2041-2053.